clinical trial · NCT04414163
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
Extranodal NK/T-cell Lymphoma, Nasal TypeExtranodal NK/T-cell LymphomaIMC-001
brief summary
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type
started
Oct 27, 2020
primary completion
Jul 23, 2024
completion
Feb 28, 2027
last updated
Apr 24, 2026
detailed description
IMC-001 is a PD-L1 targeting, fully human monoclonal antibody. The purpose of this study is to determine and evaluate the efficacy and safety of IMC-001. 20mg/kg every 2 weeks, IV infusion of IMC-001 will be tested in subjects with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type.
official title
An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol